CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Apollo Therapeutics, the portfolio biopharmaceutical company, today announces positive results from its 32-week CHAMELEON phase 2a clinical trial of ...
An expert discusses IL-18-armored CAR T cells for adults with relapsed B-cell leukemia, showing complete remissions with manageable side effects. In an onsite interview with CURE at the 2025 ASH ...
Interleukin-18 (IL-18) is a pro-inflammatory cytokine that modulates innate and adaptive immune responses. Decoy-resistant IL-18, DR-18, from Simcha Therapeutics Inc., is an engineered IL-18 cytokine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results